Hematological Malignancies

Putative mechanism(s) of action

Increased ADCC Higher affinity to the 'ADCC receptor' FcγRIIIa (GlycoMab TM technology) & Reduced CD20 internalization (?)

Increased direct cell death Type II antibody & elbow-hinge modification

FcγRIIIa Complement

Effector cell

Type II CD20 antibody

Enhanced activity in combination with chemotherapy

Reduced CDC activity Type II antibody

ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity